One To Watch

Enodia Therapeutics

A biotechnology company, based in France, developing protein-based therapeutics for immunologicals with a focus on addressing unmet medical need.

Company Overview

Enodia Therapeutics is a French biotechnology company developing small-molecule therapies for targeted protein degradation (TPD). Its proprietary platform targets the Sec61 translocon, a cellular gateway through which secreted and membrane proteins enter the secretory pathway, enabling Enodia to degrade disease-driving proteins at the point of synthesis — before they can act on their downstream targets. The approach is intended to reach proteins long considered "undruggable" by conventional inhibitors. Enodia raised a €20.7 million ($25 million) seed round in January 2026, co-led by Elaia, Pfizer Ventures and Bpifrance through its InnoBio strategy, and is advancing programmes across cancer, inflammatory and autoimmune disease, and viral infection.

Headquarters and Global Presence

Enodia Therapeutics is headquartered in France, operating within the Institut Pasteur research ecosystem in Paris. The company was incubated by Argobio Studio, a French biotech venture studio that builds companies around translational science from European academic institutions. Enodia draws on Institut Pasteur's deep expertise in immunology and microbiology and on Argobio's track record of company-formation in life sciences.

Founding and History

Enodia Therapeutics was launched in February 2025 by Argobio Studio and the Institut Pasteur to translate research on the Sec61 translocon — led by Dr Caroline Demangel, head of the Immunobiology and Therapy Unit at the Institut Pasteur — into a small-molecule drug-discovery platform. Its founding thesis is that intercepting protein synthesis at the Sec61 translocon offers a route to drug previously inaccessible secreted and membrane targets. The company emerged from stealth in January 2026 with a €20.7 million seed financing, co-led by Elaia, Pfizer Ventures and Bpifrance (InnoBio), with participation from Wallonie Entreprendre, Argobio Studio, MACSF, Institut Pasteur, InvestSud, Sambrinvest and Mission BioCapital.

Therapy Areas and Focus

Enodia's pipeline spans three therapeutic areas: oncology, inflammatory and autoimmune disease, and viral infection. In each, the company aims to degrade disease-driving secreted or membrane proteins that have proven difficult to target with conventional inhibitors. The platform's mechanism — translocon-mediated degradation — is intended to be agnostic to target druggability in the classical sense, broadening the range of biology that small molecules can address.

Technology Platforms and Modalities

Enodia's platform combines structural and chemical biology against the Sec61 translocon with proteomics and machine learning to identify which client proteins can be selectively degraded by translocon modulation. Unlike heterobifunctional degraders (PROTACs and molecular glues that act on already-folded proteins), Enodia's small molecules act at the point of protein synthesis, depleting target proteins before they reach their site of action. The company's stated aim is to expand the range of "previously undruggable" secreted and membrane targets accessible to small molecules.

Key Pipeline and Programs

Enodia has not publicly disclosed lead candidate codes or specific clinical timelines. The seed round was raised to advance the platform through target identification and lead discovery across its three therapeutic areas, with first clinical milestones to follow in subsequent financings. Investor interest from a strategic backer (Pfizer Ventures) alongside generalist and regional life-sciences funds is consistent with an early-platform stage focused on validating the Sec61 approach across multiple targets.

Key Personnel

Enodia is led by Yves Ribeill, Ph.D. (Chief Executive Officer), who previously founded Scynexis, Inc. (NASDAQ: SCYX) and served as its Chairman and CEO from 1999 to 2015. Yvonne McGrath, Ph.D. is Chief Scientific Officer. The wider leadership team includes Hélène Asnagli, Ph.D. (Associate Director of Biology), Aurore Hick, Ph.D. (Lab Head, Cell Biology and Screening) and Morgane Schwenzer (Chief of Staff). The company's Scientific Advisory Board is chaired by co-founder Caroline Demangel, Ph.D. (Institut Pasteur) and includes Michaela Müller-Trutwin, Ph.D., Stephen High, Ph.D., Alan Korman, Ph.D., Bernard Malissen, Ph.D., and Eunyong Park, Ph.D.

Strategic Partnerships

Enodia's principal institutional relationships are with the Institut Pasteur (research origin and ongoing scientific collaboration) and Argobio Studio (company formation and incubation). Its January 2026 seed round brought in Elaia, Pfizer Ventures and Bpifrance as co-leads, with participation from Wallonie Entreprendre, Argobio Studio, MACSF, Institut Pasteur, InvestSud, Sambrinvest and Mission BioCapital. Pfizer Ventures' participation in particular signals strategic interest from a major industry player in Enodia's translocon-targeting approach.

FAQ Section

Enodia's near-term challenge is to validate its Sec61 translocon-targeting platform across multiple disease areas and demonstrate that translocon-mediated degradation can produce candidate molecules with attractive selectivity, pharmacology and developability. Success in early lead-discovery and pre-clinical milestones will determine the timing and size of subsequent financings.

Targeted protein degradation has emerged as one of the most active modalities in modern drug discovery because it can address proteins that lack the binding pockets required by conventional inhibitors. Enodia extends this thesis by acting at the point of protein synthesis via the Sec61 translocon, an approach that — if validated — could expand the addressable target universe for small molecules into secreted and membrane proteins.

Enodia is differentiated by where in the protein lifecycle it intervenes. Heterobifunctional degraders (PROTACs and molecular glues) act on folded proteins via the ubiquitin-proteasome system. Enodia's small molecules act earlier, at the Sec61 translocon, intercepting proteins as they enter the secretory pathway. The platform is enabled by proteomics and machine learning to identify which client proteins can be degraded selectively.

The Sec61 translocon is the gateway through which secreted and membrane proteins — roughly a third of the human proteome — enter the secretory pathway. Selectively modulating Sec61 to degrade specific client proteins offers a route to drug targets that have historically been inaccessible to small-molecule inhibitors. Validating this thesis is the central strategic question for Enodia.

Enodia's pipeline spans three areas: oncology, inflammatory and autoimmune disease, and viral infection. Each is selected for its concentration of secreted or membrane protein targets that are difficult to drug with conventional inhibitors.

Enodia is at the platform-validation stage, advancing target identification and early lead discovery on the back of its January 2026 €20.7 million seed financing. Specific clinical-stage programmes have not been publicly disclosed.

Key watchpoints for Enodia include:

Disclosure of named lead candidates and target indications
Pre-clinical proof-of-concept data validating Sec61-mediated degradation
Timing and size of the next financing round
Strategic partnership activity (Pfizer Ventures' seed participation makes this a particular space to watch)
Competitive developments in the broader targeted-protein-degradation field

Want to Update your Company's Profile?